Eczema screening: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
*[[Hanifin and Rajka criteria]] are the gold standard for diagnosing [[eczema]]. | *[[Hanifin and Rajka criteria]] are the gold standard for diagnosing [[eczema]]. | ||
*Three out of 4 [[major criteria]], or 3 out of 23 [[minor criteria]] should be satisfied. | *Three out of 4 [[major criteria]], or 3 out of 23 [[minor criteria]] should be satisfied. | ||
*Three methods are used to assess the control of the disease, namely the repeated measurement of [[outcomes]], the number of [[medications]] used, and the occurrence of [[flares]] or [[remissions]]. | *Three methods are used to assess the control of the disease, namely the repeated measurement of [[outcomes]], the number of [[medications]] used, and the occurrence of [[flares]] or [[remissions]]. | ||
Revision as of 00:35, 26 May 2022
|
Eczema Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eczema On the Web |
|
American Roentgen Ray Society Images of Eczema |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.
Overview
Hanifin and Rajka criteria are the gold standard for diagnosing eczema. It should satisfy 3 out of 4 major criteria, or 3 out of 23 minor criteria. [1] To assess the long-term control of this disease, three methods are used, namely the repeated measurement of outcomes, the number of medications used, and the occurrence of flares or remissions.[2]
Eczema screening
- Hanifin and Rajka criteria are the gold standard for diagnosing eczema.
- Three out of 4 major criteria, or 3 out of 23 minor criteria should be satisfied.
- Three methods are used to assess the control of the disease, namely the repeated measurement of outcomes, the number of medications used, and the occurrence of flares or remissions.
References
- ↑ Schmoldt A, Benthe HF, Haberland G (1975). "Digitoxin metabolism by rat liver microsomes". Biochem Pharmacol. 24 (17): 1639–41. PMID 10.1016/j.jaad.2013.10.010. doi: 10.1016/j.jaad.2013.10.010. Check
|pmid=value (help). - ↑ Barbarot S, Rogers NK, Abuabara K, Aubert H, Chalmers J, Flohr C; et al. (2016). "Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review". J Am Acad Dermatol. 75 (5): 1038–1044. doi:10.1016/j.jaad.2016.05.043. PMID 27522613.